Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-PD-1 Antibody + Chemotherapy in Pancreatic Cancer
NCT03983057Phase 2Completed
- Sponsor
- Zhejiang University
- Start
- Apr 2019
- Primary completion
- Nov 2025
- Countries
- 1
01
Overview
Phase 2, randomised trial in pancreatic cancer (PC) (2 arms), sponsored by Zhejiang University. Primary endpoint: Event-Free Survival at 60 months. Started Apr 2019; status: completed.
02
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03983057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03983057.